Evidence map›Paper›PMID 40662118›Full record

ArticleMalaysian family physician : the official journal of the Academy of Family Physicians of Malaysia2025

Atorvastatin unveiling primary biliary cholangitis and autoimmune hepatitis overlap syndrome in an older adult: A case report.

Hashim Khadijat-Ul-Kurba, Hamzah Zuhra, Osman Ummul Afilah, Rosli Nurwahyuna

Abstract readCase Reports
In one paragraph

Article in Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hashim Khadijat-Ul-KurbaMBBS, Department of Family Medicine, Universiti Kebangsaan Malaysia, Cheras, Wilayah Persekutuan Kuala Lumpur, Malaysia. E-mail: khadijathashim@gmail.com.
Hamzah ZuhraMMed (Fam Med), Department of Family Medicine, Universiti Kebangsaan Malaysia, Cheras, Wilayah Persekutuan Kuala Lumpur, Malaysia.
Osman Ummul AfilahMBChB, Department of Pathology, Universiti Kebangsaan Malaysia, Cheras, Wilayah Persekutuan Kuala Lumpur, Malaysia.
Rosli NurwahyunaDrPath, Department of Pathology, Universiti Kebangsaan Malaysia, Cheras, Wilayah Persekutuan Kuala Lumpur, Malaysia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although statins are generally well-tolerated, recent reports have linked their use to autoimmune liver disease. We present the case of a 70-year-old woman who developed hepatocellular injury 4 months after switching from simvastatin to high-intensity atorvastatin. Discontinuation of atorvastatin led to a gradual improvement in liver function over 3 months; however, her rising LDL(low-density lipoprotein) levels prompted a rechallenge with simvastatin, resulting in recurrent liver function derangement. Despite cessation, the liver enzyme levels continued to rise. Positive autoantibodies, including antinuclear antibodies, anti-mitochondrial M2 and immunoglobulins (i.e. IgA and IgG), along with a liver biopsy, confirmed an overlapping syndrome of primary biliary cholangitis and autoimmune hepatitis. Treatment with prednisolone led to normalisation of liver function, and the patient remained stable on azathioprine and ursodeoxycholic acid. This case underscores the importance of vigilant liver function monitoring, caution when rechallenging statins and the potential for statin therapy to unmask underlying autoimmune liver disease.

Indexed as

AtorvastatinAutoimmuneAutoimmune hepatitis (AIH)Liver diseasePrimary biliary cholangitis (PBC)

Identifiers

PMID40662118
PMCPMC12258511

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.